Health Care • Biotechnology: Pharmaceutical Preparations
$4.10 ▼ -0.04
(-0.97%)
MKT CAP: $327.2M • VOL: 201.3K
52W L $1 52W H $7
ROARABLE / RQD
D- • 41/100
PIOTROSKI
4 / 9
PRLD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $12.1M | $7.0M | $0 |
| YoY Revenue Growth % | +73.4% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$104.6M | -$139.7M | -$132.3M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$99.5M | -$127.2M | -$121.8M |
| EBITDA (Normalized) | -$104.5M | -$139.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$56.3M | -$102.9M | -$107.1M |
| Capital Expenditures (CapEx) | $67.0K | $764.0K | — |
| Free Cash Flow (FCF) | -$56.4M | -$103.7M | -$107.1M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $35.3M | $12.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $68.6M | $131.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PRLD.